Alesis LLC, the U.S. distributor of the Alesis OSA1™ medical device, today announced a joint venture partnership with Dr. Lyly Fisher, DDS, Diplomate, ABDSM, ASBA — a dual board-certified sleep dentist with offices in Seattle and Renton, Washington. Dr. Fisher is the first sleep dentist in the Seattle area to offer Alesis OSA1, a breakthrough non-surgical treatment for patients with obstructive sleep apnea (OSA) who cannot tolerate CPAP therapy. The announcement marks Alesis LLC’s first West Coast location and the latest in a rapidly accelerating series of partnerships now being established at a rate of one to three new sleep centers per week.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527671910/en/
Dr. Lyly Fisher is a dual board-certified sleep dentist and Diplomate of the American Board of Dental Sleep Medicine & the American Sleep and Breathing Academy, with practices in Seattle and Renton, Washington. She specializes in the treatment of sleep-disordered breathing, with a particular focus on patients who have not achieved adequate results with CPAP or other standard therapies. Dr. Fisher is the first sleep dentist in the Seattle area to offer the Alesis OSA1 treatment program.
THE SLEEP APNEA CRISIS: A DISEASE UNDERTREATED AT SCALE
Obstructive sleep apnea affects an estimated 30 million Americans, yet remains dramatically undertreated. Patients with untreated OSA face an average reduction in life expectancy of seven years, along with significantly elevated risk for cardiovascular disease, hypertension, type 2 diabetes, stroke, and cognitive decline. Despite these stakes, compliance with CPAP — the current gold standard of therapy — is alarmingly low.
Studies consistently show that 40% to 70% of CPAP patients stop using their devices, citing discomfort from wearing a mask and hose every night, noise, claustrophobia, skin irritation, and difficulty when traveling. These patients have already gone through the full diagnostic pathway — sleep study, diagnosis, prescription, and purchase — yet remain untreated and at elevated risk. For far too long, those patients have had no meaningful non-surgical alternative. That changes with Alesis OSA1.
ALESIS OSA1™: TREATING THE ROOT CAUSE WITHOUT MASKS OR SURGERY
Alesis OSA1 is an FDA-cleared, prescription-only medical device that uses a patented, high-powered non-laser light — photonic lipolysis — to permanently reduce the localized fat deposits in the neck, tongue, throat, and airway that are the leading anatomical cause of airway obstruction in most OSA patients. The procedure requires no surgery, no needles, no anesthesia, and no recovery time. Patients receive six 12-minute in-office treatments over three weeks.
The device is manufactured in the United States by Photonica USA, LLC, in Cocoa Beach, Florida, and holds three FDA clearances (K160880, K150336, and K202361), along with 11 utility patents granted in 31 countries. The underlying technology has been FDA-cleared for over a decade with no reported side effects or adverse outcomes.
Multi-site randomized IRB clinical trials NCT06949969 at ClinicalTrials.gov demonstrated that 80% of subjects achieved a 51% to 85% improvement in sleep apnea in just three weeks, as measured by Apnea-Hypopnea Index (AHI).
THE PARTNERSHIP WITH DR. LYLY FISHER, DDS, DIPLOMATE, ABDSM, ASBA
Dr. Lyly Fisher is a Diplomate of the American Board of Dental Sleep Medicine (ABDSM) — one of the highest designations available to clinicians specializing in the dental treatment of sleep-disordered breathing. With offices in Seattle and Renton, Washington, Dr. Fisher has built a practice dedicated to helping patients who struggle with traditional OSA therapies. Her addition to the Alesis network represents the first partnership on the West Coast and a significant milestone in the company’s national expansion.
As a sleep dentist, Dr. Fisher brings a distinctive clinical perspective. She is deeply familiar with CPAP-intolerant patients — many of whom have tried oral appliances and other alternatives without adequate relief. For those patients, Alesis OSA1 offers what may be the most important innovation in non-surgical OSA care in decades: a permanent, device-free path to reducing the anatomical root cause of their condition.
“I see patients every day who are facing genuinely difficult decisions. They have been told that CPAP is their best option, they have tried sincerely, and they cannot make it work. For years, the alternatives available to them were limited — oral appliances, positional therapy, or major surgery. Alesis OSA1 changes that conversation entirely. For the right patient, it offers a clinically validated, non-surgical treatment that targets the physical source of the obstruction. I am proud to be the first provider in the Seattle area to offer this technology, and deeply committed to helping our patients achieve real, lasting improvement in their sleep and their health.”
— Dr. Lyly Fisher, DDS, Diplomate, ABDSM, ASBA, Seattle and Renton, Washington
ALESIS LLC: A NATIONAL MOVEMENT GAINING MOMENTUM
The partnership with Dr. Fisher reflects a broader national expansion that is accelerating rapidly. Alesis LLC is currently adding one to three new sleep center partnerships per week, with a growing roster of board-certified sleep medicine physicians and dentists spanning multiple states and major metropolitan markets. Following the recent launch of the flagship partnership at Lake Norman Pulmonary & Sleep in Mooresville, North Carolina — the company’s first location — announcements of new partnerships in Michigan, Texas, Georgia, Illinois, and California are expected in the near term.
For sleep medicine specialists evaluating the Alesis OSA1 platform, this expansion trajectory signals something important: this is a technology and a company with demonstrated clinical validation, a growing network of respected practitioners, and a compelling value proposition for the large and underserved population of CPAP-intolerant patients.
“Our team at Alesis is proud to be partners with Dr. Lyly Fisher. Working together, we can offer a potentially transformative non-surgical alternative for thousands of sleep apnea patients in the Seattle area.”
“Every person’s body responds differently to therapy. Nobody can guarantee an individual’s results; however, we decided as a partnership to offer a money-back guarantee if the treatment does not improve the patient’s sleep apnea by at least 50%.”
— Terry J. Ward Sr., MHA, Managing Director and CEO, Alesis LLC
PATIENT COMMITMENT: RESULTS GUARANTEE AND FLEXIBLE PAYMENT
Alesis LLC and Dr. Fisher’s practice are committed to making this treatment accessible and risk-free for qualifying patients. The program includes:
- A results guarantee: if a patient’s sleep apnea does not improve by at least 50%, they receive a full refund.
- No-interest payment plans to remove financial barriers to treatment.
- No surgery, no downtime, and no nightly wearable device.
Patients in the Seattle and Renton areas interested in learning whether Alesis OSA1 may be appropriate for their condition are encouraged to visit AlesisOSA1.com.
THE “NO MO HOSE” MOVEMENT COMES TO THE PACIFIC NORTHWEST
“No Mo Hose” is a growing patient movement that gives voice to the millions of Americans who have been diagnosed with sleep apnea, prescribed CPAP, and still go untreated every night because they cannot tolerate wearing a mask and hose. Born spontaneously at the April 2026 launch event of the Lake Norman Sleep Center in Mooresville, North Carolina, the movement has taken on a life of its own — representing a cultural and clinical inflection point in how OSA is treated in America.
With Dr. Fisher’s partnership, the No Mo Hose movement arrives in the Pacific Northwest, bringing with it a clear message for the tens of thousands of CPAP-intolerant patients in the greater Seattle area: a clinically validated, non-surgical alternative now exists — and it is available right here.
ABOUT ALESIS LLC
Alesis LLC is headquartered in Cocoa Beach, Florida, and serves as the exclusive U.S. distributor of the Alesis OSA1™ device. The company is focused on expanding access to non-surgical OSA treatment through partnerships with exemplary sleep medicine practices nationwide. Alesis LLC is led by Terry J. Ward, Sr., MHA, who invented photonic lipolysis in 2011 and its application to OSA treatment in 2025. For physician and dentist inquiries about partnership opportunities, contact Terry J. Ward, Sr. directly at 800-248-5051 or visit AlesisMedical.com.
ABOUT DR. LYLY FISHER, DDS, DIPLOMATE, ABDSM, ASBA
Dr. Lyly Fisher is a dual board-certified sleep dentist and Diplomate of the American Board of Dental Sleep Medicine & the American Sleep and Breathing Academy, with practices in Seattle and Renton, Washington. She specializes in the treatment of sleep-disordered breathing, with a particular focus on patients who have not achieved adequate results with CPAP or other standard therapies. Dr. Fisher is the first sleep dentist in the Seattle area to offer the Alesis OSA1 treatment program.
Safe Harbor / Forward-Looking Statements: This press release contains forward-looking statements regarding clinical outcomes, patient results, business expansion, and growth estimates. Actual results may vary. Clinical outcomes cited are from IRB-approved trials and individual results may differ. Alesis OSA1 is a prescription-only medical device; patients should consult their physician or qualified clinician to determine if treatment is appropriate for their condition.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260527671910/en/
Media gallery
